The trial suggests that screening could detect ovarian cancer before symptoms develop; currently, most cases are not detected until symptoms appear, by which time the cancer is at a more advanced stage.
Peter Reynolds, Chief Executive, Ovarian Cancer Action, said:
“The initial findings of this long-term study are encouraging, particularly because almost half of the ovarian cancers detected were at an early stage (stage 1), when survival rates can be as high as 90%. However, the trial still has several years until completion and the researchers will need to assess mortality rates to get a clearer idea of how effectively these screening methods translate into saving lives.
“In the absence of a national screening programme, improving awareness of the symptoms of ovarian cancer and developing a better understanding of how to treat it more effectively through investment in research, will both play a vital role in ensuring women are diagnosed with ovarian cancer at an earlier stage and they receive the most effective treatment.”